Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

Vincent Castiglione, Hans Pottel, John C Lieske, Pierre Lukas, Etienne Cavalier, Pierre Delanaye, Andrew D Rule

Research output: Contribution to journalArticle

Abstract

Background: Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease. Methods: We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a baseline visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpucMGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics. Results: There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95% CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21%) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001). Conclusion: Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. However, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.

Original languageEnglish (US)
JournalJournal of Nephrology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Kidney Calculi
Biomarkers
Serum
Logistic Models
Urine
Vascular Calcification
Cystatin C
Recurrence
Vitamin K
Kidney Diseases
Chronic Renal Insufficiency
Blood Vessels
matrix Gla protein

Keywords

  • Biomarker
  • Cystatin C
  • Matrix-Gla-protein
  • Nephrolithiais

ASJC Scopus subject areas

  • Nephrology

Cite this

Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. / Castiglione, Vincent; Pottel, Hans; Lieske, John C; Lukas, Pierre; Cavalier, Etienne; Delanaye, Pierre; Rule, Andrew D.

In: Journal of Nephrology, 01.01.2019.

Research output: Contribution to journalArticle

Castiglione, Vincent ; Pottel, Hans ; Lieske, John C ; Lukas, Pierre ; Cavalier, Etienne ; Delanaye, Pierre ; Rule, Andrew D. / Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. In: Journal of Nephrology. 2019.
@article{50cae96513eb41d9b61342c25f6835d7,
title = "Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones",
abstract = "Background: Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease. Methods: We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a baseline visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpucMGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics. Results: There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95{\%} CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21{\%}) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001). Conclusion: Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. However, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.",
keywords = "Biomarker, Cystatin C, Matrix-Gla-protein, Nephrolithiais",
author = "Vincent Castiglione and Hans Pottel and Lieske, {John C} and Pierre Lukas and Etienne Cavalier and Pierre Delanaye and Rule, {Andrew D}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40620-019-00623-0",
language = "English (US)",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

AU - Castiglione, Vincent

AU - Pottel, Hans

AU - Lieske, John C

AU - Lukas, Pierre

AU - Cavalier, Etienne

AU - Delanaye, Pierre

AU - Rule, Andrew D

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease. Methods: We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a baseline visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpucMGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics. Results: There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95% CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21%) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001). Conclusion: Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. However, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.

AB - Background: Matrix-Gla-protein (MGP) is an inhibitor of vascular calcification. Its dephosphorylated and uncarboxylated inactive form, dpucMGP, is a marker of vitamin K status and of cardio-vascular outcomes in chronic kidney disease. We hypothesized that higher serum dpucMGP would be a biomarker of kidney stone disease. Methods: We measured serum dpucMGP in incident symptomatic kidney stone-formers and non-stone formers at a baseline visit. Symptomatic stone recurrence was assessed in the stones formers over a 5-year period. The association of dpucMGP with incident or recurrent kidney stones was assessed with and without adjustment for clinical, blood, and urine characteristics. Results: There was no significant difference in serum dpucMGP level between 498 stone formers and 395 non-stone former (510 vs 501 pmol/L; p = 0.66). In a multivariable model adjusting for clinical, blood and urine chemistries, higher MGP was associated with lower risk of stone formation (OR = 0.674, 95% CI 0.522–0.870), contrary to previous reports. Among 375 stone formers with 5 years of follow-up, 79 (21%) had symptomatic recurrence. No difference in serum dpucMGP was evident in recurrent versus non-recurrent stone-formers (482 vs 502 pmol/L; p = 0.26). Serum dpucMGP was correlated with cystatin C levels in non stone-formers, incident stone-formers and recurrent stone-formers (r > 0.3, p < 0.0001). Conclusion: Elevated serum dpucMGP was not associated with incident or recurrent symptomatic kidney stone events. However, higher level of dpucMGP was associated with lower risk of kidney stone in a multivariable logistic regression model.

KW - Biomarker

KW - Cystatin C

KW - Matrix-Gla-protein

KW - Nephrolithiais

UR - http://www.scopus.com/inward/record.url?scp=85067892971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067892971&partnerID=8YFLogxK

U2 - 10.1007/s40620-019-00623-0

DO - 10.1007/s40620-019-00623-0

M3 - Article

AN - SCOPUS:85067892971

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

ER -